Shares of Zomedica Corp. (NYSEAMERICAN:ZOM) gapped down prior to trading on Tuesday . The stock had previously closed at $0.96, but opened at $0.92. Zomedica shares last traded at $0.88, with a volume of 84,548 shares traded.

Separately, Zacks Investment Research raised shares of Zomedica from a “sell” rating to a “hold” rating in a research report on Thursday, January 28th.

The firm’s 50-day moving average is $0.18.

Zomedica (NYSEAMERICAN:ZOM) last posted its quarterly earnings results on Friday, February 26th. The company reported ($0.01) earnings per share (EPS) for the quarter.

In related news, CFO Ann Marie Cotter sold 58,332 shares of the business’s stock in a transaction that occurred on Monday, April 12th. The shares were sold at an average price of $1.16, for a total transaction of $67,665.12. Following the completion of the transaction, the chief financial officer now owns 33,332 shares of the company’s stock, valued at $38,665.12. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CMO Stephanie Morley sold 805,000 shares of the business’s stock in a transaction that occurred on Monday, April 12th. The shares were sold at an average price of $1.16, for a total transaction of $933,800.00. Following the transaction, the chief marketing officer now directly owns 1,764,580 shares of the company’s stock, valued at approximately $2,046,912.80. The disclosure for this sale can be found here. In the last three months, insiders sold 1,639,176 shares of company stock worth $1,899,116.

Large investors have recently modified their holdings of the stock. International Assets Investment Management LLC purchased a new position in Zomedica during the first quarter valued at approximately $27,000. JPMorgan Chase & Co. purchased a new position in Zomedica during the third quarter valued at approximately $29,000. Optimum Investment Advisors purchased a new position in Zomedica during the first quarter valued at approximately $32,000. Private Advisor Group LLC purchased a new position in Zomedica in the 1st quarter worth approximately $39,000. Finally, Traynor Capital Management Inc. purchased a new position in Zomedica in the 1st quarter worth approximately $53,000.

Zomedica Company Profile (NYSEAMERICAN:ZOM)

Zomedica Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies.

See Also: How Do Mutual Funds Work?

Receive News & Ratings for Zomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica and related companies with MarketBeat.com's FREE daily email newsletter.